EN | UA
EN | UA

Help Support

Back

Molnupiravir treatment is well-tolerated in COVID-19 patients

Molnupiravir for COVID Molnupiravir for COVID
Molnupiravir for COVID Molnupiravir for COVID

What's new?

For the management of outpatients with SARS-CoV-2 infection, Molnupiravir is well-tolerated and associated with favorable outcomes.

According to a single-center study, Molnupiravir showed good tolerability and was related to favorable COVID-19 outcomes. In order to determine if the patient profile and short-term COVID-19 results are similar to those of clinical trial subjects from the pivotal MOVe-OUT study, Anca Streinu-Cercel et al. analyzed data concerning the real-world therapeutic usage of Molnupiravir.

Complete clinical data were available for 46 outpatients who were given Molnupiravir treatment; 56.5% (n = 20) of these patients were men with median age of 48.5 years (Interquartile range [IQR]: 37.8, 67.0 years). The percentage of subjects with a minimum 1 chronic disease was 54.2% (n = 26). Notably, 28.9% (13 out of 45) individuals who had their lungs examined using lung computed tomography imaging had alterations indicative of SARS-CoV-2 pneumonia.

Presence of SARS-CoV-2 vaccine was highly protective against pneumonia. All individuals had symptoms, and Molnupiravir was started 3.5 (±1.5) days on average after the onset of symptoms. All subjects, with the exception of 1, confirmed a favorable course under intervention, with severity of SARS-Co-2 infection not getting worse, and betterment in symptoms; none of them needed hospitalization or advanced to respiratory failure.

This was done 5 days after the initial assessment and the start of Molnupiravir intervention. In routine practice, Molnupiravir therapy was well-tolerated and linked to positive COVID-19 results in a clinical population that was somewhat older, had fewer comorbidities, and had a greater incidence of COVID-19 immunization than that from the pivotal study.

Source:

Pharmaceuticals

Article:

Real-World Use of Molnupiravir in the Treatment of Outpatients with SARS-CoV-2 Infection—A Patient Profile Based on the Experience of a Tertiary Infectious Disease Center

Authors:

Anca Streinu-Cercel et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: